JP2006506942A5 - - Google Patents

Claims (18)

  A peptide comprising at least 3 and less than 15 amino acid residues and comprising an amino acid sequence as shown in SEQ ID NO: 7.   The peptide according to claim 1, wherein the amino acid sequence further comprises an amino acid having no polar charge selected from the group consisting of serine, threonine, asparagine, glutamine and natural derivatives thereof.   The peptide of claim 1, wherein the amino acid sequence further comprises at least one positively charged amino acid and at least one negatively charged amino acid.   4. The peptide of claim 3, wherein the at least one positively charged amino acid is selected from the group consisting of lysine, arginine, and their natural and synthesized derivatives.   4. The peptide of claim 3, wherein the at least one negatively charged amino acid is selected from the group consisting of aspartic acid, glutamic acid, and their natural and synthesized derivatives.   The peptide according to claim 1, wherein the amino acid sequence is selected from the group consisting of SEQ ID NO: 4, SEQ ID NO: 12 to SEQ ID NO: 19, and SEQ ID NO: 27 to SEQ ID NO: 45.   The peptide according to claim 1, wherein the peptide is selected from the group consisting of SEQ ID NO: 4, SEQ ID NO: 12 to SEQ ID NO: 19, and SEQ ID NO: 27 to SEQ ID NO: 45.   The peptide of claim 1 further comprising at least two serine residues at its C-terminus.   The peptide of claim 1, wherein the peptide further comprises at least one β-breaker amino acid.   The peptide according to claim 9, wherein the β-breaker amino acid is proline.   Use of a peptide according to claim 1 for the manufacture of a medicament for treating or preventing an amyloid-related disease in an individual.   A pharmaceutical composition for treating or preventing an amyloid-related disease, comprising a peptide having an amino acid sequence of at least 3 and less than 15 and comprising the amino acid sequence as shown in SEQ ID NO: 7 as an active ingredient A pharmaceutical composition comprising and comprising a pharmaceutically acceptable carrier or diluent.   A nucleic acid construct comprising a polynucleotide segment encoding a peptide having at least 3 and less than 15 amino acid residues and comprising an amino acid sequence as shown in SEQ ID NO: 7.   The nucleic acid construct according to claim 13, further comprising a promoter.   An antibody or antibody fragment comprising an antigen recognition region comprising at least 3 and less than 15 amino acid residues and capable of binding to a peptide comprising the amino acid sequence as shown in SEQ ID NO: 7.   A pharmaceutical composition for treating or preventing an amyloid-related disease, comprising at least 3 and less than 15 amino acid residues and binding to a peptide comprising an amino acid sequence as shown in SEQ ID NO: 7 A pharmaceutical composition comprising, as an active ingredient, an antibody or antibody fragment having a possible antigen recognition region.   An amyloid-related disease in an individual of an antibody or antibody fragment comprising an antigen recognition region comprising at least 3 and less than 15 amino acid residues and capable of binding to a peptide comprising an amino acid sequence as shown in SEQ ID NO: 7 Use for the manufacture of a medicament for treatment or prevention.   18. Use according to claim 17, wherein the antibody or antibody fragment is an active ingredient of a pharmaceutical composition which also comprises a physiologically acceptable carrier.